Evolutec says hay fever drug candidate may have anti-inflammatory properties


evolutecLONDON (AFX) - Evolutec Group plc, a biopharmaceutical company developing products for the treatment of allergic, inflammatory and autoimmune diseases, said its hay fever drug candidate rEV131 has demonstrated an additional mechanism that may give it anti-inflammatory properties.

It said rEV131, currently in Phase IIb trial, has an equivalent impact to an experimental small molecule H4 receptor blocker which may explain its anti-inflammatory effects, such as the significant reduction in nasal congestion observed, in previous clinical trials in asthma.

'We believe that rEV131 has the potential to fill the unmet need in allergic rhinitis for a new product which has a fast onset and reduces all symptoms,' it said.

Evolutec also said it is on schedule to deliver the results of its North American 300-patient Phase IIb hay fever trial by the year-end.